Skip to main content

Table 3 One way s ensitivity analysis

From: Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)

 

Arm A

Arm B

ICER B/A

 

Costs € / utility

Costs €/ utility

€/QALY

Base case

27 734 €/0.51

31 688 €/ 0.52

395400

Utility of patients treated by erlotinib

   

−20% (0.538)

27 734 €/ 0.48

31 688 €/ 0.51

131800

−10% (0.606)

27 734 €/0.51

31 688 €/ 0.52

395400

+10% (0.740)

27 734 €/ 0.54

31 688 €/ 0.54

NA

+20% (0.807)

27 734 €/ 0.57

31 688 €/ 0.55

NA

Post-progression cost

   

1627 €

25 954 €/ 0.51

28 787 €/ 0.52

283300

3021 €

29 514 €/ 0.51

34 588 €/ 0.52

507400

Erlotinib tariff

   

−30%

24 282 €/ 0.51

29 788 €/ 0.52

550600

+ 30%

31 186 €/ 0.51

33 588 €/ 0.52

240200

  1. Arm A: erlotinib followed by docetaxel and gemcitabine (DG); Arm B: DG followed by erlotinib.